touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)” (Abstract 455) was presented at the 2021 Genitourinary Cancers Symposium, 11–13 February 2021.
- Could you give us a brief overview of upper tract urothelial carcinoma, its prognosis and the unmet needs in its treatment? (0:05)
- What did the POUT trial teach us about the clinical utility of adjuvant chemotherapy in upper tract urothelial cancer? (2:13)
- You have already talked about the updated primary and secondary endpoints, could you also continue to update us on the other secondary endpoints? (6:50)
- How will these findings impact clinical practice? (9:48)
Disclosure: Dr Alison Birtle has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 Genitourinary Cancers Symposium (Virtual), 11–13 February 2021.
Birtle AJ, Chester JD, Jones R, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol. 2021;36(Suppl. 6):407.
Share this Video
Related Videos In Genitourinary Cancers
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!